Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CWT-F-002
- Development stage
- Phase 1
- Lead developer
- Calm Water Therapeutics
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**CWT-F-002** is a preservative-free, unit-dose lubricant ophthalmic solution developed by Calm Water Therapeutics for **dry eye disease**. It contains glycerin 0.7% and polyethylene glycol 400 0.4% as OTC-monograph active ingredients, with mannitol, polylysine-graft-polyethylene glycol, sterile water for injection, and sodium phosphate buffer as inactive ingredients. It is intended to supplement and stabilize the ocular surface tear film, providing lubrication and reducing dry-eye signs and symptoms. A completed randomized, double-masked clinical study compared CWT-F-002 with preservative-free Systane eye drops in adults with dry eye disease.
Beyond the preview
Go deeper on CWT-F-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CWT-F-002.